

Naveen Kella, MD
Urology San Antonio
7909 Fredericksburg Rd.
San Antonio, Texas 78229

EDUCATION:

1990-1994	Stanford University Stanford, California Bachelor in Science, Chemical Engineering
1994-1998	University of Texas Southwestern Medical Dallas, Texas Medicine
1998-1999	Tufts, New England Medical Center Boston, Massachusetts Internship
1999-2002	Tufts, New England Medical Center Boston, Massachusetts Residency
2002-2003	Tufts, New England Medical Center Boston, Massachusetts Chief Residency
2003-2004	Baylor College of Medicine Houston, Texas Fellowship, Urologic Oncology

WORK EXPERIENCE:

2006-Present	Urology San Antonio Research, PA San Antonio, Texas 78229 Investigator
2004-Present	Urology San Antonio, PA 7909 Fredericksburg Rd. Suite 120 San Antonio, Texas 78229 Group Practice-Urologist
2004-2006	Urology San Antonio, PA 315 N. San Saba Suite 1295 San Antonio, Texas 78207 Group Practice-Urologist

CREDENTIALS:

Diplomate, American Board of Urology

PUBLICATIONS:

1. Kella, N., Slawin K.M., “Robotic Radical Prostatectomy: Extraperitoneal Approach,” Video Abstract, accepted, Society of Laparoendoscopic Surgeons Annual Meeting 2004
2. Slawin, K.M., “Robotic Radical Retropubic Prostatectomy using the Da Vinci System: Perspectives of a Urologic Oncologist,” Video Abstract, AUA Annual Meeting 2004
3. Kella,N., Slawin, K.M., “What is Transrectal Ultrasound?”Book Chapter, American Cancer Society Prostate Cancer Book, 2004, in press
4. Kella, N., Slawin, K.M., “Options in Transrectal Ultrasound?’ Book Chapter, American Cancer Society Prostate Cancer Book, 2004,in press
5. Gurevitch, E.J., Kella, N., Gapin, T. et al. “Urinary flow rate recording: the Impact of a single dose of a diuretic on clinic logistics and flow rate parameters.” J Urol., 161:1509,1999

PRESENTATIONS:

1. Robotics in Urology “Baylor College of Medicine Grand Rounds” March 2004
2. BPH- Pathophysiology and Perspectives in Evaluation “Tufts Department of Urology Grand Rounds” 2002
3. Superficial Bladder Cancer- Current and Future Management “Tufts Department Of Urology Grand Rounds” 2002
4. Characteristics of Lower Urinary Tract Symptoms Affecting Candidacy for Transurethral Microwave Thermotherapy “ AUA Annual Meeting, 2001, Moderated Poster
5. Prostate Biopsies “Tufts Department of Urology Grand Rounds” 2001
6. Cryoablation of Peripheral Renal Masses “Podium presentation at New England section AUA 2000 meeting”

AWARDS:

- 2003 Pfizer Scholars in Urology Award
- 2002-2003 Praecis Pharmaceuticals/ AUA Gerald P. Murphy Scholar

CLINICAL RESEARCH EXPERIENCE:

1. “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of XXXXXX for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia.”
2. “Feasibility Evaluation of the XXXXXX in Facilitating the XXXXXX following a Radical Prostatectomy.”

3. "A Phase III Randomized, Open-Label Study of XXXXXX and XXXXXX Versus and XXXXXX in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy Naïve."
4. "A Multicenter, Open-Label, Randomized, Phase III Trial Comparing XXXXXX in Combination with XXXXXX Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy."
5. "A Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing with XXXXXX to Treat the Symptoms of Overactive Bladder"
6. "Post-Marketing Study Using XXXXXX for the Treatment of Benign Prostatic Hyperplasia."
7. "A Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of XXXXXX in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management."
8. "A Phase 1 Trial of XXXXXX for locally Recurrent Prostate Cancer without Metastases after Primary Radiation Therapy."
9. "A Feasibility Evaluation of the XXXXXX Device in Facilitating the Vesico-urethral Anastomosis Following a Radical Prostatectomy."
10. "A Phase III Multi-Center, Open-Label, Randomized Evaluation in Hypogonadal Male Subjects of the Pharmacokinetics and Safety of a Dose Regimen of XXXXXX, a Novel Testosterone Transmucosal Film Formulation, and Striant (Testosterone Buccal System) Mucoadhesive."
11. "A Phase III, open-label, multi-center study of the efficacy and safety of XXXXXX in the treatment of Patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG."
12. "A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Spermatogenesis in Health Male Subjects During Administration of XXXXXX."
13. "A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trail of XXXXXX 50 milligrams Daily and, with Uptitration, 100 Milligrams Daily in Premenopausal Women with Hypoactive Sexual Desire Disorder."
14. "A Phase III Radomized, Open-Label Study of XXXXXX and XXXXXX Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate cancer who are Chemotherapy-Naïve."
15. "Post-Marketing Study Using XXXXXX for the Treatment of Benign Prostatic Hyperplasia (BPH)."
16. "A Multi-Center Clinical Study of the XXXXXX for the Treatment of Localized (T1cT2a) Prostate Cancer with HIFU."
17. "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of XXXXXX in Extending the Time to Progression of Low-Risk Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management."
18. "XXXXXX 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life."

19. "A Phase II Randomised, Two-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone following application of different XXXXX doses in hypogonadal male subjects."
20. "A Phase 1 Trial of XXXXX Therapy for locally Recurrent Prostate Cancer without Metastases after Primary Radiation Therapy."
21. "A Multicentre, Placebo Controlled, Randomised, Double-Blind, Dose Ranging Study of XXXXX and Placebo Daily Doses for 4 Weeks in Patients Suffering From Overactive Bladder Syndrome."
22. "A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (XXXXX) in combination with XXXXX Administred Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk After Radical Prostatectomy."
23. "Pilot Study of the Intervesimal Administration of XXXXX Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer."
24. "Phase Ib placebo-controlled trial of XXXXX in the study of modulation of intermediate endpoint markers in patients with prostate cancer who are undergoing prostatectomy."
25. "A Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing with XXXXX to Treat the Symptoms of Overactive Bladder with a 14-Week Open-Label Safety Extension."
26. "A randomized double blind phase III study to evaluate adjuvant XXXXX treatment versus placebo in patients with clear cell XXXXX and high risk of recurrence."
27. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
28. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
29. "A Randomized, Double-Blind, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of XXXXX in Men with Prostate Cancer Receiving Androgen Deprivation Therapy."
30. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXXXX for the Treatment of Hypogonadal Men."
31. "An Open-Label, Multi- Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of XXXXX One-Month Dosing Regimen in Patients with Prostate Cancer Requiring XXXXX."
32. "Long Term Effectiveness Trial for AMS Sling Systems MiniArc"
33. "A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXX vs. XXXXX in Combination XXXXX in Patients with Metastatic Hormone-Resistant Prostate Cancer and Bone Metastasis who are Pain-Free or Mildly Symptomatic"
34. "A Phase 3 Randomized, Open-Label Study of XXXXX in Combination with XXXXX and XXXXX Versus XXXXX and XXXXX in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain"
35. "TITAN OTR Clinical Trial"

36. "Evaluation of the PCA3 Assay and Algorithms Combining PCA3 Score with Other Factors for the Prediction of Biopsy Outcome and Pathological Stage"
37. "A Phase I, Randomized, Double-Blind, Placebo Controlled Assessment of the Safety, Tolerability and Activity of XXXXX Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection"
38. "A Randomized, Double-Blind, Placebo Controlled, Parallel- Design, Multicenter Study to Evaluate the Urodynamic Effects of XXXXX Once-A-Day for 12 Weeks In Men with Signs and Symptoms of Benign Prostatic Hyperplasia"
39. "An Open-Label, Phase 3 Study of XXXXX Testosterone Gel 2% in Hypogonadal Males"
40. "A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a XXXXX in Comparison with XXXXX in Patients with Overactive Bladder"
41. "Prospective Randomized Double-Blind Study of Sperm Production in Healthy Volunteers Receiving XXXXX or Placebo"
42. "An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients with Locally Recurrent Prostate Cancer After Primary Radiation Therapy"
43. "A Multicenter, Open Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy in Combination with XXXXX Administered Every 3 Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy"
44. "A Phase 3, Multi-Center, Open-Label Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two 6-Month XXXXX Formulations in Subjects with Prostatic Adenocarcinoma"
45. "Performance Evaluation of Optimized Kit Components and Process"
46. "GeneSearch Prostate Methylation Urine (Pro Mu) Assay"
47. "A Randomized, Double-Blind, Placebo Controlled Multicenter Cross over study to Investigate the Pharmacodynamic Profile of XXXXX in Subjects with Pelvic Pain of Bladder Origin"
48. "A Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of a Novel Nutritional Supplement on PSA Kinetics in Men with Biochemical Recurrence after Definitive Therapy for Prostate Cancer"
49. "A Phase II/III Controlled Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects with a History of Stress Urinary Incontinence"
50. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of XXXXX for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women"
51. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXXXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women"

52. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXXXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women"
53. "A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 12.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men with Both Erectile Dysfunction and Benign Prostatic Hyperplasia"
54. "XXXXX 2.5 mg and 5 mg once a Day Compared to Placebo in Day of Onset of Efficacy"
55. "Phase 3 Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Clinical Evaluation of XXXXX for the Treatment of BPH"
56. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of XXXXX, in Patients with Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hypertrophy (BPH)"
57. "Study of Urgent PC vs. Sham Effectiveness in Treatment of Overactive Bladder Symptoms"
58. "Efficacy and Safety of a New XXXXX 11.25mg Depot Formulation, XXXXX, When Given as Palliative Treatment to Prostate Cancer Patients"
59. "Hypoactive Sexual Desire Disorder in Women Registry"
60. "Validation of the AutoFISH XXXXX Bladder Cancer Kit on the XXXXX Automated Slide Staining System Specimen Collection and Specimen Testing Protocol"
61. "A Phase III, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered XXXXX in 10mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients"